EP Patent

EP4139289A1 — Inhibitors of human epididymus protein 4

Assigned to University of Rochester · Expires 2023-03-01 · 3y expired

What this patent protects

The present disclosure provides compounds of Formula I for use in the treatment of medical disorders by the inhibition of human epididymal protein 4 (HE4).

USPTO Abstract

The present disclosure provides compounds of Formula I for use in the treatment of medical disorders by the inhibition of human epididymal protein 4 (HE4).

Drugs covered by this patent

Patent Metadata

Patent number
EP4139289A1
Jurisdiction
EP
Classification
—
Expires
2023-03-01
Drug substance claim
No
Drug product claim
No
Assignee
University of Rochester
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.